Aspect Biosystems plans clinical data in 2027 from cell therapy pipeline, CEO says at Meeting on the Mesa
Sartorius says one operator can run eight cell therapy patients on Eveo platform at Meeting on the Mesa
CGT Catapult pitches ‘federation’ to lower cell and gene therapy development costs at Meeting on the Mesa
BOOST Pharma outlines placebo-controlled trial of up to 80 patients for brittle bone cell therapy BT-101 at Meeting on the Mesa
Tamer Mohamed told Cell & Gene Meeting on the Mesa that Aspect Biosystems plans to generate clinical data in 2027, and set out preclinical data for its adrenal insufficiency and type 1 diabetes programs.
Published 7 Oct 2026
Sartorius chief technology officer Oscar-Werner Reif told the Cell & Gene Meeting on the Mesa the company believes its automated Eveo platform can bring cell therapy costs below $40,000 per patient.
Published 7 Oct 2026
Stephen Ward, chief technology officer of the UK’s Cell and Gene Therapy Catapult, told Meeting on the Mesa that developers can share data, testbeds and manufacturing space without losing control.
Published 7 Oct 2026
CEO Hans Schambye told Cell & Gene Meeting on the Mesa that BOOST Pharma expects to be able to start a placebo-controlled trial of BT-101, its investigational stem cell therapy for osteogenesis imperfecta, in the middle of next year.
Published 7 Oct 2026
Tim Hunt told Cell & Gene Meeting on the Mesa that Wall Street data point to seven more cell and gene therapy blockbusters, and said ARM will soon announce changes to its membership dues.
Published 6 Oct 2026
Karim Mikhail told Cell & Gene Meeting on the Mesa the FDA wants eventually to bring its separate rare disease efforts into one package, and set out how the Expedited IND Pilot is meant to speed up first-in-human trials.
Published 6 Oct 2026
CEO Gaurav Shah said a product enriched for full capsids drove the dose cut in the pivotal Danon trial, ahead of an investor webinar on updated Phase 1 data on October 6.
Published 6 Oct 2026
CEO Devyn Smith presented preclinical data from gene editing programs for ALS, with a first CNS IND filing targeted for 2027.
Published 6 Oct 2026
The Vancouver immunologist on myeloid cells as a delivery route, STING for cold tumours, and why in vivo CAR could land near the price of a checkpoint inhibitor.
Published 15 Sep 2026
The Cambridge founder on re-engineering antibodies to break into solid tumours, raising a seed round without a professor behind her, and why hiring in the UK is her hardest problem.
Published 7 Sep 2026
CamMed CEO Dr. Ahmet Can Berkyurek on an AI-discovered, single-protein replicase drawn from biology's most ancient machinery — and his case for building it in the UK
Published 30 Jul 2026
Zidesamtinib produced responses in 44% of 117 patients who had already taken a ROS1 inhibitor, and in 48% of those with measurable brain metastases.
Published 22 Jul 2026
The FDA has granted Orphan Drug designation to Affinia Therapeutics' AFTX-201, a one-time IV gene therapy for BAG3-associated dilated cardiomyopathy. It follows a recent Fast Track grant; AFTX-201 is in the Phase 1/2 UPBEAT trial recruiting across the U.S. and Canada.
Published 22 Jul 2026
CEO Rob Etherington and chief scientist Mark Mortenson on the bioenergetic thesis behind CNM-Au8, the HEALEY data, and five meetings with the agency.
Published 21 Jul 2026
Enlicitide cut LDL-C by 56% against placebo in a 2,904-patient trial, putting PCSK9 inhibition into a once-daily tablet.
Published 15 Jul 2026
Gedatolisib plus fulvestrant and palbociclib reached 9.3 months median progression-free survival against 2.0 on fulvestrant alone.
Published 14 Jul 2026
